Curiox Biosystems has signed a Master Software License Agreement with a major global pharmaceutical company to deploy Pluto Code, its centrifuge-free cell washing software, across multiple liquid-handling workstations and sites under a single contract. This agreement streamlines expansion by eliminating repeated contract negotiations, facilitating faster and broader adoption of automation in labs. Pluto Code runs on existing lab robots without new hardware, validated on major platforms like Hamilton and Tecan. This deal marks a shift from early adoption to enterprise-level deployment, highlighting Pluto Code's maturity and potential to standardize workflows globally.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Bitcoin price recently hit a strong resistance level at $65,600 but failed to break through, signaling a possible reversal. Short-term momentum is weakening, suggesting the price may decline unless a sudden surge occurs. Key support levels include th...
